USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Moderna saw its shares close up 9% yesterday and up more than 17% at $47.64 in pre-market trading today, after revealing a financing deal for its COVID-19 vaccine candidate. 17 April 2020
The USA’s Blackstone revealed today that it will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases. 14 April 2020
Privately-held US biotech EpiVax yesterday announced its partnership with GAIA Vaccine Foundation (GVF) to crowd-source funds for the COVID-19 project and its pledge to make a free license available to developing countries who qualify, in the context of this partnership. 8 April 2020
The Proteo-Science Center at Japan’s Ehime University and drugmaker Sumitomo Dainippon Pharma today announced that the pre-clinical development project for a new malaria transmission-blocking vaccine (TBV), which the two organizations are jointly conducting with US non-profit organization PATH, has been awarded a grant from the Global Health Innovative Technology Fund (GHIT Fund). 3 April 2020
India’s Department of Pharmaceuticals (DoP) has proposed an incentive scheme worth around 10,000 billion rupees ($1.3 billion) aiming to strengthen the domestic active pharmaceutical ingredients (APIs) facilites to boost domestic manufacturing in India to compensate for dwindling Chinese supply because of the coronavirus outbreak. 26 March 2020
US biotech firm Dragonfly Therapeutics today announced an expansion of its strategic collaboration with Merck & Co to discover, develop and commercialize a number of Dragonfly's candidate natural killer (NK) cell engager immunotherapies for oncology, infectious disease, and immune disorders. 19 March 2020
US biotech Microbiotix has been awarded up to $2.86 million in non-dilutive funding by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) to develop a new oral antibiotic to treat multidrug-resistant gonorrhea. 17 March 2020
Shares of Israeli biotech firm Protalix BioTherapeutics, which are also traded in New York, were up 10.6% at $2.61 in morning activity, after the company said it has successfully secured securities purchase agreements to raise $43.7 million through a private equity investment (PIPE) in the company. 12 March 2020
British research charity Wellcome and The Bill and Melinda Gates Foundation are each to contribute $50 million to a new fund to fight COVID-19. 11 March 2020
UK company George Health has announced £27 million ($35 million) in new financing to accelerate the commercialization of drugs and technologies for some of the world’s most destructive diseases. 10 March 2020
Osaka, Japan-headquartered Shionogi has moved a step closer to taking full ownership of rare disease specialist and co-developer Tetra Therapeutics. 6 March 2020
Japanese pharma giant Takeda Pharmaceutical is selling off $825 million worth of products in Latin America, part of the firm’s ultimate goal to divest non-core assets to the value of $10 billion. 3 March 2020
Privately-held UK-based T cell receptor (TCR) biotech firm Immunocore today announced the completion of its Series B private financing round, generating more than $130 million. 2 March 2020
Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), has expressed “deep concern” at a long-term trend of research and development activity moving to other regions. 2 March 2020
Ireland-incorporated Theravance Biopharma has closed a $400 million private financing round, with fixed rate term notes secured by expected royalties from Trelegy Ellipta. 2 March 2020
Amid growing interest in the potential for non-opioid pain-related treatments in the USA, Israel's RedHill Biopharma has bought rights to Movantik (naloxegol), from AstraZeneca. 25 February 2020
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news